Browsing by Author "Nikitović, Marina (6602665617)"

Background: Medulloblastoma has one of the highest rates of metastasis outside the central nervous system (CNS). Bone metastases are the most common lesions, although lymph node and visceral spread have also been reported. Objective: To present patients with bone metastasis in medulloblastoma and discuss their radiologic appearances and treatment approach. Patients and methods: From 1993 to 2008, 82 patients diagnosed with medulloblastoma were treated at the Institute for Oncology and Radiology of Serbia. Three (3.6%) developed extraneural metastasis (ENM). In primary treatment, patients were treated with surgery, craniospinal radiotherapy with local boost to tumor bed, and adjuvant chemotherapy 'lomustine (CCNU) and vincristine'. Of the three patients with ENM, all developed bone metastases at the time of relapse. Relapse occurred within 17 to 42 months of initial diagnosis. Patients received secondary chemotherapy and palliative radiotherapy to the affected bone in two cases. Results: Among these three patients, case 1 had initially a solitary lytic lesion. Case 2 had diffuse blastic lesions and also bone marrow involvement. Case 3 had multiple mixed lytic-sclerotic lesions but later developed lymph node metastasis and metastases to both breasts, as well. All patients were without concurrent CNS involvement at the time of ENM. Unfortunately, after initial partial response, the three patients died at 24, 13, and 18 months after detection of metastases, respectively. Conclusion: With prolonged survival times in children with medulloblastoma, more emphasis should be placed on the possibility of systemic involvement. A greater understanding of the pathogenesis of the systemic metastases may be valuable in designing future, more aggressive multimodal therapy. © 2013 Informa Healthcare USA, Inc.

Background: The goal of research was to investigate the possible relations between serum concentrations of IL-6 and TGF-β1, individual and clinical characteristics, and adverse effects of radiotherapy in patients with prostate cancer: acute and late genitourinary and gastrointestinal toxicity, and fatigue. Methods: Thirty-nine patients with localized or locally advanced prostate cancer who were treated with radiotherapy were enrolled in this study. The acute radiotoxicity grades and fatigue levels were assessed during the radiotherapy and 1 month after the radiotherapy. Estimation of the late radiotoxicity was performed every three months in the first year, every four months in the second year, and then every six months. Serum levels of IL-6 and TGF-β1 were determined before radiotherapy and after the 25th radiotherapy fraction by ELISA. Results: The significant positive association between diabetes mellitus and changes in acute genitourinary toxicity grades during the radiotherapy was observed in prostate cancer patients. In addition, patients who were smokers had significantly higher maximum fatigue levels in comparison with patients who were non-smokers. The circulating IL-6 levels were significantly higher after the 25th radiotherapy fraction in comparison with levels determined before radiotherapy. The significant positive correlations between pretreatment TGF-β1 levels and maximum genitourinary toxicity grades and between TGF-β1 levels after the 25th fraction and genitourinary toxicity grades after the 25th fraction, were found. The pretreatment IL-6 concentrations and TGF-β1 concentrations after the 25th fraction were positively correlated with maximum genitourinary toxicity grades. The IL-6 levels after the 25th fraction were positively associated with genitourinary toxicity grades after this fraction. The pretreatment IL-6 concentrations were significantly positively correlated with maximum fatigue scores. The significant positive correlation between IL-6 concentrations and fatigue scores after the 25th fraction was determined. The positive correlations between IL-6 and TGF-β1 concentrations measured after the 25th fraction and maximum fatigue scores were observed. Conclusions: Our results suggest that serum levels of IL-6 and TGF-β1 might influence the severity of acute genitourinary radiotoxicity and fatigue in patients with prostate cancer. Combining clinical parameters and circulating cytokine levels might be useful for the prediction of adverse reactions to radiotherapy. © 2022, The Author(s).

Background: The goal of research was to investigate the possible relations between serum concentrations of IL-6 and TGF-β1, individual and clinical characteristics, and adverse effects of radiotherapy in patients with prostate cancer: acute and late genitourinary and gastrointestinal toxicity, and fatigue. Methods: Thirty-nine patients with localized or locally advanced prostate cancer who were treated with radiotherapy were enrolled in this study. The acute radiotoxicity grades and fatigue levels were assessed during the radiotherapy and 1 month after the radiotherapy. Estimation of the late radiotoxicity was performed every three months in the first year, every four months in the second year, and then every six months. Serum levels of IL-6 and TGF-β1 were determined before radiotherapy and after the 25th radiotherapy fraction by ELISA. Results: The significant positive association between diabetes mellitus and changes in acute genitourinary toxicity grades during the radiotherapy was observed in prostate cancer patients. In addition, patients who were smokers had significantly higher maximum fatigue levels in comparison with patients who were non-smokers. The circulating IL-6 levels were significantly higher after the 25th radiotherapy fraction in comparison with levels determined before radiotherapy. The significant positive correlations between pretreatment TGF-β1 levels and maximum genitourinary toxicity grades and between TGF-β1 levels after the 25th fraction and genitourinary toxicity grades after the 25th fraction, were found. The pretreatment IL-6 concentrations and TGF-β1 concentrations after the 25th fraction were positively correlated with maximum genitourinary toxicity grades. The IL-6 levels after the 25th fraction were positively associated with genitourinary toxicity grades after this fraction. The pretreatment IL-6 concentrations were significantly positively correlated with maximum fatigue scores. The significant positive correlation between IL-6 concentrations and fatigue scores after the 25th fraction was determined. The positive correlations between IL-6 and TGF-β1 concentrations measured after the 25th fraction and maximum fatigue scores were observed. Conclusions: Our results suggest that serum levels of IL-6 and TGF-β1 might influence the severity of acute genitourinary radiotoxicity and fatigue in patients with prostate cancer. Combining clinical parameters and circulating cytokine levels might be useful for the prediction of adverse reactions to radiotherapy. © 2022, The Author(s).

Febrile neutropenia is a serious adverse effect of chemotherapy. It can lead to complications and death, as well as delays in treatment, chemotherapy dose reductions, compromised treatment efficacy, and reduced survival. The assessment of the patient-related risk factors plays a significant role in the prevention of febrile neutropenia and its complications. In the case of intermediate-risk chemotherapy, the patient-related factors contribute to the estimation of an overall febrile neutropenia risk as well as to timely planning of primary prophylaxis using growth factors. Patients presenting with febrile neutropenia undergo a detailed initial risk assessment for serious complications so that an appropriate treatment can be selected. Recommendations given by the guidelines outline the classification of and risk factors for febrile neutropenia complications. The use of patient-related factors and validated tools for the risk assessment of complications makes it possible to optimize the treatment for each patient and to reduce the risk of morbidity and mortality due to febrile neutropenia. © 2022, Serbia Medical Society. All rights reserved.

Introduction/Objective Isocitrate dehydrogenase (IDH) mutations play a significant role in gliomagenesis. Specific microRNAs, such as microRNA-10b and microRNA-21, act as oncogenic microRNAs, whereas microRNA-34a acts as a tumor suppressor in glioblastoma. Our study aimed to investigate whether the IDH1 mutation status correlates with microRNA-10b,-21, and-34a expression levels in patients with glioblastoma. Methods The study included 43 patients diagnosed with glioblastoma. We examined microRNA-10b,-21, and-34a expression levels in peripheral blood mononuclear cells after surgery and prior to concurrent radiotherapy with temozolomide, as well as at the 15th and 30th fractions of radiotherapy with temozolomide. Data on IDH1 mutation status were gathered from medical histories and histopathology. Results Two groups were created to assess the association of microRNA-10b,-21, and-34a expression levels: glioblastoma IDH1-wildtype and glioblastoma IDH1-mutant + not otherwise specified (NOS). The median microRNA-10b expression level before the initiation of concurrent radiotherapy with temozolomide was 130.44 (52.2–622.53) in the IDH1-wildtype group and 94.61 (2.13–816.89) in the IDH1-mutant + NOS group. The median microRNA-21 expression level was 57.16 (2.68–278.98) in the IDH1-wildtype group and 69.74 (4.6–825.43) in the IDH1-mutant + NOS group. The median microRNA-34a expression level was 13.52 (3.16–105.20) in the IDH1-wildtype group and 10.11 (1–210.55) in the IDH1-mutant + NOS group. The results showed no statistically significant difference in the expression levels of microRNA-10b,-21, or-34a between the two groups (p > 0.05). Conclusion Our findings suggest that IDH1 mutation status may not be a critical factor for altered expression of microRNA-10b,-21, and-34a in glioblastoma patients. © 2025, Serbia Medical Society. All rights reserved.

Personalized radiation treatment is an important goal in radiation oncology. As a result, one of the main challenges in radiobiology today is predicting a patient’s tissue radiosensitivity so that a personalized treatment can be tailored to that individual. For the first time since 2016, a group from the Institute of Oncology and Radiology of Serbia has begun performing translational research in the field of radiobiology. The aim of these studies is to identify molecular markers important for the prediction of radiosensitivity as well as the occurrence of toxic effects of radiotherapy. In the past five years, significant international cooperation has been established with the Radiogenomic Consortium, as well as leading European and world experts in this field. In addition, during this period, several significant and promising results in this field were published, and a Laboratory for Radiobiology was established at the Institute of Oncology and Radiology of Serbia. © 2022, Serbia Medical Society. All rights reserved.

The prediction of induction chemotherapy response at the time of diagnosis may improve outcomes in osteosarcoma by allowing for personalized tailoring of therapy. The aim of this study was thus to investigate the predictive potential of the so far unexploited computational analysis of osteosarcoma magnetic resonance (MR) images. Fractal and gray level cooccurrence matrix (GLCM) algorithms were employed in retrospective analysis of MR images of primary osteosarcoma localized in distal femur prior to the OsteoSa induction chemotherapy. The predicted and actual chemotherapy response outcomes were then compared by means of receiver operating characteristic (ROC) analysis and accuracy calculation. Dbin, λ, and SCN were the standard fractal and GLCM features which significantly associated with the chemotherapy outcome, but only in one of the analyzed planes. Our newly developed normalized fractal dimension, called the space-filling ratio (SFR) exerted an independent and much better predictive value with the prediction significance accomplished in two of the three imaging planes, with accuracy of 82% and area under the ROC curve of 0.20 (95% confidence interval 0-0.41). In conclusion, SFR as the newly designed fractal coefficient provided superior predictive performance in comparison to standard image analysis features, presumably by compensating for the tumor size variation in MR images. © 2017 Djuricic, Radulovic, Sopta, Nikitovic and Miloševic.

The prediction of induction chemotherapy response at the time of diagnosis may improve outcomes in osteosarcoma by allowing for personalized tailoring of therapy. The aim of this study was thus to investigate the predictive potential of the so far unexploited computational analysis of osteosarcoma magnetic resonance (MR) images. Fractal and gray level cooccurrence matrix (GLCM) algorithms were employed in retrospective analysis of MR images of primary osteosarcoma localized in distal femur prior to the OsteoSa induction chemotherapy. The predicted and actual chemotherapy response outcomes were then compared by means of receiver operating characteristic (ROC) analysis and accuracy calculation. Dbin, λ, and SCN were the standard fractal and GLCM features which significantly associated with the chemotherapy outcome, but only in one of the analyzed planes. Our newly developed normalized fractal dimension, called the space-filling ratio (SFR) exerted an independent and much better predictive value with the prediction significance accomplished in two of the three imaging planes, with accuracy of 82% and area under the ROC curve of 0.20 (95% confidence interval 0-0.41). In conclusion, SFR as the newly designed fractal coefficient provided superior predictive performance in comparison to standard image analysis features, presumably by compensating for the tumor size variation in MR images. © 2017 Djuricic, Radulovic, Sopta, Nikitovic and Miloševic.

Primary spinal cord germinomas are an extremely rare group of tumors, most commonly reported as single cases in young Japanese adults. They usually present as intramedullary lesions located in the thoracic and thoracolumbar spine. The importance of preoperative diagnosis lies in the fact that by using radiotherapy and chemotherapy, even without surgery, a good cure rate can be achieved in patients with spinal cord germinoma. These tumors, however, demonstrate unspecific imaging characteristics, and only some secrete tumor markers. Therefore, a diagnosis of these lesions before biopsy or resection with pathohistologic examination can be difficult. We present a case of a 28-year-old white man with intramedullary spinal cord germinoma. The tumor was resected completely with electrophysiological monitoring, without a biopsy and frozen section analysis. Postoperative radiotherapy also was part of the treatment. The patient has had no relapse 4.5 years after diagnosis; however, significant neurologic deficits remain. Although not as frequent in white patients, germinoma should be considered as differential diagnosis in cases of young adult patients with intramedullary tumor in the thoracic or thoracolumbar spine. Therefore, spinal mass surgery should commence with a biopsy and intraoperative frozen section analysis. In this way, attempting a gross total resection becomes unnecessary. With an approach of intraoperative biopsy and frozen section analysis, a considerable amount of postoperative neurologic deficits can be reduced. © 2016 Elsevier Inc.

We describe long-lasting and incompletely resolved thrombocytopenia after transient profound pancytopenia in a 62-year-old female patient with glioblastoma after short-term radiotherapy with temozolomide. Pancytopenia was present for more than 4 weeks and thrombocytopenia for more than 6 months, without platelet recovery to normal levels. Learning Points • Some patients may experience severe haematological manifestations after even short-term radiotherapy with temozolomide. • In everyday practice, clinical models precisely predicting the haematological toxicity of concomitant treatment with temozolomide and radiotherapy is necessary, especially in countries where genetic tests are not available. • Incomplete recovery of the cells of a particular bloodline over a long period may necessitate permanent discontinuation of chemotherapy or radiotherapy. © 2020 EFIM.

Objectives The aim of this study was to contribute to the standardization of the numeric positive enhancement integral (PEI) values in breast parenchyma, ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC) and to evaluate the significance of the difference in PEI values between IDC and parenchyma, DCIS and parenchyma and IDC and DCIS. Materials and Methods In the prospective trial, we analyzed the dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) of 60 consecutive patients with histologically confirmed unilateral DCIS (n = 30) and IDC (n = 30) and defined the PEI values (range; mean ± SD) for the lesions and the breast parenchyma. Tumor-to-non-tumor (T/NT) ratios were calculated for DCIS and IDC and compared. PEI color maps (PEICM) were created. The differences in PEI values between IDC and parenchyma and between DCIS and parenchyma were tested according to t-test. Analysis of variance (ANOVA) was used to test the differences between the mean PEI values of parenchyma, DCIS and IDC. Results IDC showed highly statistically different PEI numeric values compared to breast parenchyma (748.7 ± 32.2 vs. 74.6 ± 17.0; p < 0.0001). The same applied to the differences in the group of patients with DCIS (428.0 ± 25.0 vs. 66.0 ± 10.6; p < 0.0001). The difference between IDC, DCIS and parenchyma were also considered highly statistically significant (p < 0.0001) and so were the T/NT ratios for IDC and DCIS (10.1 ± 2.4 vs. 6.6 ± 1.4; p < 0.0001). Conclusions PEI numeric values may contribute to differentiation between invasive and in situ breast carcinoma. © 2014 Elsevier Ireland Ltd.

Proton beam therapy (PBT) is an advanced type of radiotherapy that shows a dosimetric advantage over photon beam therapy and provides superior dose distribution. PBT may improve patient survival by improving the local disease control while reducing toxicity to normal organs, which may result in fewer treatment-related complications. During the last decade, technological progress has opened up new possibilities in the planning and conducting of PBT, so indications have gradually expanded to different cancers. However, many biological aspects of PBT are still unclear, and its role in clinical settings is con-troversial. Proton therapy is considered to be safe and effective for different types of pediatric cancers, and suitable in treatment of ocular melanomas, chordomas, and chondrosarcomas. Future research and more prospective clinical studies with long-term follow-up are required in order to clearly determine the benefits and proper indications for PBT. © 2021, Serbia Medical Society. All rights reserved.

Cancer patients are at high risk for developing severe symptoms with a high mortality rate due to infection of COVID-19. Radiation therapy is one of the main treatment modalities of central nervous system tumors and lung cancer. Radiotherapy is often delivered in a number of fractions, which implies many visits to the radiotherapy center and thus possibly more exposure to the COVID-19. The convenient compromise between the exposure of the patients to the SARS-CoV-2 virus and the optimal treatment is questionable. The most used measures in radiotherapy centers are classification of patients into priority groups and frequent use of hypofractionation. From the beginning of the COVID-19 outbreak, only a few expert group consensuses of radiotherapy treatment are published. In this paper we briefly review available practical recommendations of the expert groups for radiation therapy and oncology as well as the expert opinions for radiotherapy of the central nervous system tumors and lung cancer during the COVID-19 pandemic. © 2020, Serbia Medical Society. All rights reserved.

Introduction/Objective In glioblastoma, upregulation of oncogenic microRNA-10b (miR-10b) and microRNA-21 (miR-21) is often found. Our study aimed to investigate whether there is a link between miR-10b and miR-21 expression levels and tumor size and tumor localization. Methods The research involved 43 patients diagnosed with glioblastoma. We analyzed the expression levels of miR-10b and miR-21 post-surgery. The data on tumor size and tumor localization were obtained from magnetic resonance imaging. Results The median expression level of miR-10b in patients with tumors < 4 cm was 214.86 (min–max: 2.13–816.89), while in patients with tumors ≥ 4 cm, the median expression level was 92.99 (min–max: 19.24–491.82). The median expression level of miR-21 in patients with tumors < 4 cm was 81.69 (min– max: 11.39–825.43), whereas in patients with tumors ≥ 4 cm, the median expression level was 40.84 (min–max: 2.68–278.98). For both miR-10b and miR-21, a statistically significant difference was found for tumors < 4 cm (p = 0.027 and p = 0.047, respectively) compared to those ≥ 4 cm. There was no statistically significant difference in the expression levels of miR-10b (p = 0.675) and miR-21 (p = 0.183) in relation to tumor localization. Conclusion Glioblastomas smaller than 4 cm have statistically significantly higher expression levels of miR-10b and miR-21 compared to glioblastomas equal to or larger than 4 cm. Although this result is unexpected, it could mean that miR expression levels dynamically change after surgery and according to the altered microenvironment. © 2025, Serbia Medical Society. All rights reserved.

Purpose: More than half of prostate cancer patients undergo radiation treatment which may be accompanied by acute or late side effects in genitourinary, GU, and/or gastrointestinal, GI tract, and radiotherapy-induced fatigue (RIF). The biological role of RNase L highlights its potential to be tested for association with the adverse effects of radiotherapy. Objectives: This study aims to investigate the associations among RNASEL gene variants, acute, late GI/GU toxicity events, and RIF to evaluate their potential to be used as biomarkers for prediction of response to radiation treatment. Methods: The DNA from peripheral blood mononuclear cells of 81 patients with prostate adenocarcinoma under RT was genotyped for RNASEL rs12757998, rs486907, and rs627928 by real-time quantitative PCR. The acute and late GU and GI adverse effects were evaluated during and up to 54 months after RT, as well as the occurrence or increase in fatigue grade. Results: rs12757998 RNASEL TT genotype was shown to be significantly associated with severity of acute GU toxicity while CT genotype with severity of late GI toxicity. Furthermore, CC genotype of rs12757998 and the AA genotype of rs627928 were shown to be potential independent predictive biomarkers of RIF. Conclusion: RNASEL gene polymorphisms are associated with a higher risk of radiotoxicity, which may be used for biological tests for the prediction of RT-related side effects and to develop strategies to fight against fatigue, to significantly improve the quality of life of cancer survivors. © Copyright © 2025 Taylor & Francis Group LLC.

Stereotactic body radiotherapy (SBRT) is the standard treatment for early-stage inoperable non-small cell lung cancer. SBRT achieves a high local control rate (74–100%), preserves the quality of life, and the treatment is of low-toxicity. Different fractionation regimens are used, depending on the localization and size of the tumor, the proximity of the organs at risk, and the general condition of the patient. The radiobiology behind SBRT is largely unknown, precisely defined radiation doses and the number of fractions are still a matter of debate. Numerous studies are ongoing regarding the standardization of SBRT in lung cancer treatment. © 2024, Serbia Medical Society. All rights reserved.

Objective: Atypical and anaplastic meningiomas (World Health Organization classification grade II and III) represent a small and heterogeneous subgroup of meningiomas that has a more aggressive biological nature and higher frequency of recurrence. The atypical form accounts for 4.7%-7.2%, whereas the anaplastic type accounts for 1%-2.8% of all meningiomas. The aim of this study is to evaluate the role of postoperative radiotherapy on overall survival and progression-free survival in patients operated for atypical and anaplastic meningiomas. Methods: A retrospective analysis of the patients operated at the Clinic of Neurosurgery, Clinical Center of Serbia, Belgrade, between January 1, 1995 and December 31, 2006 was performed. In that period 88 lesions met the histologic criteria for atypical (75) and anaplastic (13) meningiomas. Postoperative radiotherapy was conducted in 63.6% of patients. Results: At a median follow-up of 67.4 months the overall survival was 68 months and the 5-year survival was about 54.5%. The median survival was 76 months with surgery and adjuvant radiotherapy and 40 months with surgery alone (log rank = 7.4; P = 0.006). Recurrent disease occurred in 58 patients (65.9%). Median time between first surgery and tumor recurrence in patients undergoing radiotherapy was 51 months, whereas in the nonirradiated group it was 24 months (log rank = 17.7; P < 0.001). Multivariate analysis identified as recurrence-predicting factors anaplastic histotype (hazard ratio = 2.9; P = 0.003) and postoperative radiotherapy (hazard ratio = 4.5; P < 0.001). Conclusions: The addition of adjuvant radiotherapy to surgery for atypical and anaplastic meningiomas resulted in a clinically meaningful and statistically significant survival benefit. © 2015 Elsevier Inc. All rights reserved.

Malignant pleural mesothelioma (MPM) is a rare malignancy with poor prognosis. In recent years, sig-nificant progress has been made in the treatment of this disease, including surgical and radiotherapy techniques, systemic therapy, and immunotherapy. Due to the wide range of clinical presentations, a lack of phase-III randomized trials, and heterogeneity in treatment approach, the treatment of MPM remains challenging regardless of available diagnostic and therapeutic guidelines. The limited possibility to avoid critical healthy organs (particularly lungs), overexposure of which can lead to severe, and even fatal, radiation-induced toxicity, makes high-dose radical radiotherapy very demanding. Thus, the majority of patients in the era of conventional radiotherapy were mostly referred to no more than palliative radiotherapy. Technological development in radiotherapy such as respiratory gating, 4D computed tomography, intensity-modulated radiotherapy, volumetric modulated arc therapy, stereotactic techniques, and proton therapy, made a step forward in treating MPM with this modality. Today, MPM radiotherapy can be considered in various indications, alone or in combination with surgery and systemic treatment. However, many questions remain open, and further investigation is needed especially in dose escalation possibility and lung sparing. © 2024, Serbia Medical Society. All rights reserved.

Purpose: The aim was to evaluate the total diagnostic interval (TDI) and presenting complaints in children with brain tumours in Serbia. Methods: This study retrospectively analysed 212 children aged 0–18 years newly diagnosed with brain tumours in two tertiary centres from mid-March 2015 to mid-March 2020 covering virtually all children with brain tumours in Serbia. TDI was calculated as the difference between the date of diagnosis and the date of symptom onset presented as a median in weeks. This variable has been evaluable for 184 patients. Results: Overall TDI was 6 weeks. TDI was significantly longer in patients with low-grade tumours (11 weeks) than in patients with high-grade tumours (4 weeks). Children with the most frequent complaints (headache, nausea/vomiting and gait disturbance) were more likely to be diagnosed sooner. Patients with a single complaint had significantly longer TDI (12.5 weeks) contrasted to patients with multiple complaints (5 weeks). Conclusion: TDI with a median of 6 weeks is similar to other developed countries. Our study supports the view that low-grade tumours will present later than high-grade tumours. Children with the commonest complaints and children with multiple complaints were more likely to be diagnosed sooner. © 2023, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Background: Choosing the optimal treatment approach for patients with painful bone metastases during the COVID-19 pandemic became challenging. A simple technique, single fraction radiotherapy was recommended for these patients usually referring to bone metastases as a single entity, although it is a very heterogeneous group of patients. Aim: This study aimed to analyze the response to palliative single fraction radiotherapy in relation to age, performance status, primary tumor, histopathology, and bone localization in the group of patients with painful bone metastases. Methods: A clinical, prospective, non-randomized study was conducted at the Institute for Oncology and Radiology of Serbia, which included 64 patients with noncomplicated, painful bone metastases who underwent palliative, pain-relieving radiation therapy with a single tumor dose of 8Gy in a single hospital visit. Response to treatment was patient reported via telephone interview using visual analog scale. The response assessment was based on the international consensus panel of radiation oncologists. Results: In the entire group of patients, 83% responded to radiotherapy. No statistically significant difference was observed in response to therapy, time to reach the maximum response, degree of pain reduction, nor in response duration depending on the patient's age, performance status, the primary origin of the tumor, histopathology, or location of the metastasis (bone) that was irradiated. Conclusion: Regardless of clinical parameters, palliative radiotherapy with a single dose of 8Gy can be considered very effective in quick pain relief in patients with noncomplicated painful bone metastases. Single fraction radiotherapy in a single hospital visit, as well as patient-reported outcome for these patients may be considered favorable beyond Covid pandemics. © 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.